First Trust SMID Growth Strength ETF FSGS
33.33 USD +0.44 (+1.33%)
At closeNov 11, 2026, 4:00 PM EST
33.33 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
33.28 Day range 33.33
28.45 52-week range 34.15
- YTD
- +9.52%
- 1 year
- +8.53%
News
benzinga.com What's Going On With Docusign Stock Wednesday? Docusign (DOCU) stock jumped 2%+, approaching its $75 52-week high despite broader tech declines. Expanded Salesforce deal boosts momentum.
gurufocus.com CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesPR NewswireMELBOURNE, Australia and BASEL,
gurufocus.com Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
gurufocus.com Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
gurufocus.com Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen
gurufocus.com Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f